Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex Pharmaceuticals has launched Incivek (telaprevir) tablets used for the treatment of liver disease in Canada.
Subscribe to our email newsletter
Incivek is used for people with genotype 1 chronic hepatitis C with compensated liver disease including cirrhosis.
The drug has been approved by Health Canada for use in combination with pegylated-interferon and ribavirin, which also help in the treatment of hepatitis C.
The Canadian approval of the drug candidate occurred following a global Phase 3 clinical trial that yielded positive results.
The trial which comprised over 2,500 people with hepatitis C demonstrated higher rates of viral cure in patients who received Incivek combination treatment as compared to those who received pegylated-interferon and ribavirin alone.